{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:33:20Z","timestamp":1778884400298,"version":"3.51.4"},"reference-count":87,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous disease. Most patients achieve long-lasting remissions and have excellent overall survival (OS) with current treatment. However, \u223c20% of patients have early progression of disease and short OS. At present, therapies are not guided by individual risk or disease biology. Reliable tools for patient stratification are urgently needed to avoid overtreatment of low-risk patients and to prioritize alternative approaches in high-risk patients. A rapidly expanding repertoire of promising therapeutic options is available for clinical evaluation; however, the numbers of patients with FL and the resources to conduct adequately powered trials are limited. Recent studies have shown that gene mutations can serve as prognostic and\/or predictive biomarkers, in particular when integrated into composite risk models. Before translating these findings into routine clinical practice, however, several challenges loom. We review aspects of \u201cclinicogenetic\u201d risk model development and validation that apply to FL and more generally to other cancers. Finally, we propose a crowdsourcing effort that could expedite the development, validation, refinement, and selection of risk models. A new era of collaboration and harmonization is required if we hope to transition from empiric selection of therapeutics to risk-based, biology-guided treatment of patients with FL.<\/jats:p>","DOI":"10.1182\/blood-2017-07-737353","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T09:54:13Z","timestamp":1502186053000},"page":"1491-1498","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["The promises and challenges of using gene mutations for patient stratification in follicular lymphoma"],"prefix":"10.1182","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0987-7373","authenticated-orcid":false,"given":"Oliver","family":"Weigert","sequence":"first","affiliation":[{"name":"Department of Medicine III, University Hospital, Ludwig Maximilian University, Munich, Germany;"},{"name":"German Cancer Consortium, Heidelberg, Germany;"},{"name":"German Cancer Research Center, Heidelberg, Germany;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and"},{"name":"Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"1","key":"2019111903574599800_B1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111903574599800_B2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"2019111903574599800_B3","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"23","key":"2019111903574599800_B4","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111903574599800_B5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111903574599800_B6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.6004\/jnccn.2010.0021","article-title":"NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin\u2019s lymphomas","volume":"8","author":"Zelenetz","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"2019111903574599800_B7","volume-title":"Ann Oncol","author":"Dreyling","year":"2016"},{"issue":"8","key":"2019111903574599800_B8","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111903574599800_B9","doi-asserted-by":"crossref","first-page":"djw255","DOI":"10.1093\/jnci\/djw255","article-title":"Recommendations for clinical trial development in follicular lymphoma","volume":"109","author":"Maddocks","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2019111903574599800_B10","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2006-10-041863","article-title":"How I treat indolent lymphoma","volume":"109","author":"Gribben","year":"2007","journal-title":"Blood"},{"issue":"7","key":"2019111903574599800_B11","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/leu.2014.91","article-title":"How we manage follicular lymphoma","volume":"28","author":"Hiddemann","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2019111903574599800_B12","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2019111903574599800_B13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood-2017-03-691345","article-title":"Can histologic transformation of follicular lymphoma be predicted and prevented?","volume":"130","author":"Kridel","year":"2017","journal-title":"Blood"},{"issue":"17","key":"2019111903574599800_B14","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","article-title":"Follicular lymphoma: evolving therapeutic strategies","volume":"127","author":"Kahl","year":"2016","journal-title":"Blood"},{"issue":"7360","key":"2019111903574599800_B15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"7337","key":"2019111903574599800_B16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"issue":"4","key":"2019111903574599800_B17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","article-title":"Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma","volume":"129","author":"Krysiak","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2019111903574599800_B18","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1182\/blood-2013-05-500264","article-title":"Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"issue":"18","key":"2019111903574599800_B19","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"B\u00f6d\u00f6r","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2019111903574599800_B20","doi-asserted-by":"crossref","first-page":"E1116","DOI":"10.1073\/pnas.1501199112","article-title":"Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111903574599800_B21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"issue":"1","key":"2019111903574599800_B22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of follicular lymphoma transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Reports"},{"issue":"2","key":"2019111903574599800_B23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/ng.3473","article-title":"Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma","volume":"48","author":"Okosun","year":"2016","journal-title":"Nat Genet"},{"issue":"1","key":"2019111903574599800_B24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2016.175","article-title":"Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma","volume":"31","author":"Bouska","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"2019111903574599800_B25","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2012-09-457283","article-title":"Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma","volume":"121","author":"Green","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2019111903574599800_B26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.immuni.2014.12.021","article-title":"Enhancer sequence variants and transcription-factor deregulation synergize to construct pathogenic regulatory circuits in B-cell lymphoma","volume":"42","author":"Koues","year":"2015","journal-title":"Immunity"},{"issue":"8","key":"2019111903574599800_B27","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1182\/blood-2015-12-682591","article-title":"Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations","volume":"128","author":"Louissaint","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2019111903574599800_B28","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/2159-8290.CD-16-1417","article-title":"The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma","volume":"7","author":"Zhang","year":"2017","journal-title":"Cancer Discov"},{"issue":"10","key":"2019111903574599800_B29","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/nm.3940","article-title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat Med"},{"issue":"10","key":"2019111903574599800_B30","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3943","article-title":"The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development","volume":"21","author":"Ortega-Molina","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"2019111903574599800_B31","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP inactivation promotes the development of HDAC3-dependent lymphomas","volume":"7","author":"Jiang","year":"2017","journal-title":"Cancer Discov"},{"issue":"19","key":"2019111903574599800_B32","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2016-08-733469","article-title":"Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice","volume":"129","author":"Garc\u00eda-Ram\u00edrez","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2019111903574599800_B33","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2010-11-321208","article-title":"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation","volume":"117","author":"Yap","year":"2011","journal-title":"Blood"},{"issue":"7427","key":"2019111903574599800_B34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"issue":"5","key":"2019111903574599800_B35","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"B\u00e9guelin","year":"2013","journal-title":"Cancer Cell"},{"issue":"3","key":"2019111903574599800_B36","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.cell.2011.09.035","article-title":"The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma","volume":"147","author":"Oricchio","year":"2011","journal-title":"Cell"},{"issue":"6","key":"2019111903574599800_B37","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of \u03b22-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"issue":"7530","key":"2019111903574599800_B38","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature13765","article-title":"Loss of signalling via G\u03b113 in germinal centre B-cell-derived lymphoma","volume":"516","author":"Muppidi","year":"2014","journal-title":"Nature"},{"issue":"4","key":"2019111903574599800_B39","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/blood-2014-06-582650","article-title":"Activating STAT6 mutations in follicular lymphoma","volume":"125","author":"Yildiz","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111903574599800_B40","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cell.2016.08.032","article-title":"Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells","volume":"167","author":"Boice","year":"2016","journal-title":"Cell"},{"issue":"9","key":"2019111903574599800_B41","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"2019111903574599800_B42","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1182\/blood-2014-04-571786","article-title":"BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2019111903574599800_B43","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1038\/bcj.2017.32","article-title":"EZH2 alterations in follicular lymphoma: biological and clinical correlations","volume":"7","author":"Huet","year":"2017","journal-title":"Blood Cancer J"},{"issue":"6","key":"2019111903574599800_B44","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/ajh.24701","article-title":"BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab","volume":"92","author":"Huet","year":"2017","journal-title":"Am J Hematol"},{"issue":"8","key":"2019111903574599800_B45","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3324\/haematol.2017.165415","article-title":"Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"102","author":"Stevens","year":"2017","journal-title":"Haematologica"},{"issue":"22","key":"2019111903574599800_B46","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1158\/0008-5472.CAN-10-2460","article-title":"Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis","volume":"70","author":"Cheung","year":"2010","journal-title":"Cancer Res"},{"issue":"8","key":"2019111903574599800_B47","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood.V82.8.2289.2289","article-title":"p53 mutations are associated with histologic transformation of follicular lymphoma","volume":"82","author":"Lo Coco","year":"1993","journal-title":"Blood"},{"issue":"7","key":"2019111903574599800_B48","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood.V82.7.1994.1994","article-title":"p53 mutation is associated with progression in follicular lymphomas","volume":"82","author":"Sander","year":"1993","journal-title":"Blood"},{"issue":"3","key":"2019111903574599800_B49","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/leu.2011.266","article-title":"High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis","volume":"26","author":"Launay","year":"2012","journal-title":"Leukemia"},{"issue":"33","key":"2019111903574599800_B50","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: predictive or prognostic?","volume":"33","author":"Ballman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111903574599800_B51","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2008-05-154013","article-title":"The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival","volume":"112","author":"O\u2019Shea","year":"2008","journal-title":"Blood"},{"issue":"12","key":"2019111903574599800_B52","doi-asserted-by":"crossref","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","article-title":"Histological transformation and progression in follicular lymphoma: a clonal evolution study","volume":"13","author":"Kridel","year":"2016","journal-title":"PLoS Med"},{"issue":"2","key":"2019111903574599800_B53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"issue":"3","key":"2019111903574599800_B54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nri3814","article-title":"Germinal centres and B cell lymphomagenesis","volume":"15","author":"Basso","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"suppl S2","key":"2019111903574599800_B55","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/hon.2437_85","article-title":"Evaluation of clinicogenetic risk models for outcome of follicular lymphoma patients in the PRIMA trial","volume":"35","author":"Huet","year":"2017","journal-title":"Hematol Oncol"},{"issue":"27","key":"2019111903574599800_B56","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"2019111903574599800_B57","volume-title":"Haematologica","author":"Araf","year":"2016"},{"issue":"364","key":"2019111903574599800_B58","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"issue":"21","key":"2019111903574599800_B59","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.139.139","article-title":"Monitoring of circulating tumor DNA as minimal residual disease in diffuse large B-cell lymphoma","volume":"124","author":"Roschewski","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2019111903574599800_B60","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"25","key":"2019111903574599800_B61","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2016-03-635219","article-title":"Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma","volume":"127","author":"Roschewski","year":"2016","journal-title":"Blood"},{"issue":"32","key":"2019111903574599800_B62","doi-asserted-by":"crossref","first-page":"11278","DOI":"10.1073\/pnas.0502738102","article-title":"Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation","volume":"102","author":"Matsuzaki","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"2019111903574599800_B63","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"issue":"1","key":"2019111903574599800_B64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2159-8290.CD-11-0208","article-title":"Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation","volume":"2","author":"Weigert","year":"2012","journal-title":"Cancer Discov"},{"issue":"13","key":"2019111903574599800_B65","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1182\/blood-2012-05-414995","article-title":"The evolving contribution of hematopoietic progenitor cells to lymphomagenesis","volume":"120","author":"Weigert","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2019111903574599800_B66","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.20130977","article-title":"BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups","volume":"211","author":"Berres","year":"2014","journal-title":"J Exp Med"},{"issue":"suppl S2","key":"2019111903574599800_B67","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/hon.2437_2","article-title":"John Ultmann Memorial Lecture: Genomes in transit: what multi-omics can tell us on lymphomas","volume":"35","author":"Siebert","year":"2017","journal-title":"Hematol Oncol"},{"issue":"5","key":"2019111903574599800_B68","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","article-title":"Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy","volume":"160","author":"Montero","year":"2015","journal-title":"Cell"},{"issue":"9","key":"2019111903574599800_B69","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-15-2023","article-title":"Toward personalized lymphoma immunotherapy: identification of common driver mutations recognized by patient CD8+ T cells","volume":"22","author":"Nielsen","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111903574599800_B70","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrc3774","article-title":"The tumour microenvironment in B cell lymphomas","volume":"14","author":"Scott","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"2019111903574599800_B71","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3923.3923","article-title":"STAT6 is recurrently and significantly mutated in follicular lymphoma and enhances the IL-4 induced expression of membrane-bound and soluble CD23","volume":"126","author":"Bosl","year":"2015","journal-title":"Blood"},{"key":"2019111903574599800_B72","volume-title":"Leukemia","author":"Pangault","year":"2010"},{"issue":"15","key":"2019111903574599800_B73","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1182\/blood-2015-02-625152","article-title":"CD10 delineates a subset of human IL-4 producing follicular helper T cells involved in the survival of follicular lymphoma B cells","volume":"125","author":"Am\u00e9-Thomas","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111903574599800_B74","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111903574599800_B75","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2012.44.2137","article-title":"Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation","volume":"31","author":"Kiaii","year":"2013","journal-title":"J Clin Oncol"},{"key":"2019111903574599800_B76","volume-title":"N Engl J Med","author":"Tibshirani","year":"2005"},{"key":"2019111903574599800_B77","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.2437_103","article-title":"Gene-expression profiling predicts disease progression in follicular lymphoma","volume":"35","author":"Huet","year":"2017","journal-title":"Hematol Oncol"},{"key":"2019111903574599800_B78","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/hon.2437_3","article-title":"Interim report from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory B-cell non-Hodgkin lymphomas","volume":"35","author":"Morschhauser","year":"2017","journal-title":"Hematol Oncol"},{"issue":"3","key":"2019111903574599800_B79","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat Med"},{"issue":"12","key":"2019111903574599800_B80","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/nm.3968","article-title":"SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2","volume":"21","author":"Kim","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"2019111903574599800_B81","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111903574599800_B82","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"2019111903574599800_B83","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom\u2019s Macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"issue":"12","key":"2019111903574599800_B84","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMp1607591","article-title":"Toward a shared vision for cancer genomic data","volume":"375","author":"Grossman","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"2019111903574599800_B85","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2015-01-623777","article-title":"A roadmap for discovery and translation in lymphoma","volume":"125","author":"Weinstock","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2019111903574599800_B86","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3324\/haematol.2015.136739","article-title":"The European Hematology Association Roadmap for European Hematology Research: a consensus document","volume":"101","author":"Engert","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"2019111903574599800_B87","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/13\/1491\/1402413\/blood737353.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/13\/1491\/1402413\/blood737353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T03:58:23Z","timestamp":1574135903000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/13\/1491\/36522\/The-promises-and-challenges-of-using-gene"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,28]]},"references-count":87,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2017,9,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-07-737353","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,28]]}}}